Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium adolescentis iVS-1
- Development stage
- Preclinical
- Lead developer
- Synbiotic Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
iVS-1 is a specific probiotic strain of *Bifidobacterium adolescentis* developed by Synbiotic Health. It is characterized as a next-generation probiotic intended to improve gut health through multiple mechanisms, including the modulation of the gut microbiota and the enhancement of gut barrier integrity. Clinical studies have demonstrated that iVS-1 can reduce intestinal permeability by upregulating the production of tight-junction proteins and mucin. Furthermore, the strain has been shown to alleviate symptoms of lactose intolerance in lactose maldigesters by enhancing lactase gene expression and improving lactose digestion. iVS-1 is also noted for its ability to produce gamma-aminobutyric acid (GABA) and folate, which may provide additional benefits for the gut-brain axis, cardiovascular health, and immune function.
- Brand names
- iVS-1iVS1iVS 1
- Other names
- Bifidobacterium adolescentis iVS-1iVS-1iVS1iVS 1
02
Targets
OCLN (Occludin)MUC2 (Mucin-2)LCT (Lactase-phlorizin hydrolase)
Beyond the preview
Go deeper on Bifidobacterium adolescentis iVS-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium adolescentis iVS-1.